Pharma Bio Services AI Stock Analysis
Want to see PBSV full AI Analyst Report?
Pharma Bio Services (PBSV) AI Stock Analysis
Pharma Bio Services
(Other OTC:PBSV)
The score is held down primarily by weak financial performance—recent losses and sustained negative cash flow—despite the stabilizing benefit of a very low-debt balance sheet. Technicals add pressure with the stock below major moving averages and only mild momentum signals. Valuation provides limited support because negative earnings make P/E unusable and no dividend yield is available.
Pharma Bio Services (PBSV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $11.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,255
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 0.59
- Revenue Growth
- 3.25%
- EPS Growth
- ―
- Country
- US
- Employees
- 55
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Pharma Bio Services Business Overview & Revenue Model
Company Description
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the ph...
How the Company Makes Money
null
Pharma Bio Services Financial Statement Overview
Summary
Overall fundamentals are pressured by recent operating losses and a sharp deterioration in profitability (2024–2025 and TTM) alongside deeply negative operating/free cash flow (cash burn). The key offset is an unusually strong balance sheet with near-zero debt and sizable equity, which reduces near-term financial risk but does not fix weak returns and negative cash conversion.
Income Statement
38NegativeBalance Sheet
82Very PositiveCash Flow
29Negative| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.48M | 9.00M | 9.51M | 16.98M | 19.40M | 20.12M |
| Gross Profit | 3.07M | 2.91M | 2.52M | 5.07M | 4.88M | 5.36M |
| EBITDA | -24.26K | 134.81K | -1.11M | 1.31M | 1.23M | -3.78M |
| Net Income | -13.95M | -100.46K | -777.62K | 1.31M | 1.01M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 11.44B | 13.65M | 16.29M | 19.90M | 20.65M | 23.92M |
| Cash, Cash Equivalents and Short-Term Investments | 8.58M | 10.85M | 12.75M | 14.98M | 14.46M | 17.47M |
| Total Debt | 0 | 28.83K | 194.03K | 346.51K | 487.36K | 617.42K |
| Total Liabilities | 994.74M | 1.74M | 2.58M | 3.78M | 4.09M | 5.01M |
| Stockholders Equity | 10.44B | 11.91M | 13.72M | 16.13M | 16.56M | 18.91M |
Cash Flow | ||||||
| Free Cash Flow | -304.53M | -221.53K | -726.44K | 1.88M | 573.19K | 794.00K |
| Operating Cash Flow | -304.53M | -214.89K | -566.70K | 1.89M | 592.46K | 804.84K |
| Investing Cash Flow | -2.21B | -1.47M | -1.36M | -4.22M | -19.27K | 1.30M |
| Financing Cash Flow | -1.72B | -1.75M | -1.73M | -1.76M | -3.53M | -1.75M |
Pharma Bio Services Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Positive. The current price of 0.50 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.47, and below the 200-day MA of 0.51, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.56 is Neutral, neither overbought nor oversold. The STOCH value of 83.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBSV.
Pharma Bio Services Risk Analysis
Pharma Bio Services disclosed 25 risk factors in its most recent earnings report. Pharma Bio Services reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPharma Bio Services Peers Comparison
Overall Rating
- PBSV43Neutral
ZCMD43Neutral
VSEE41Neutral
HCTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PBSV | 43Neutral | $11.45M | -1.39 | -0.27% | ― | 3.25% | ― |
| ZCMD | 43Neutral | $4.27M | -0.00 | -53.52% | ― | -49.58% | -31.56% |
| VSEE | 41Neutral | $564.25K | -0.03 | -400.87% | ― | -9.31% | 89.42% |
| HCTI | 38Underperform | $3.73M | -0.00 | -56.46% | ― | 116.40% | 99.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PBSV | Pharma Bio Serv Inc | 0.50 | 0.03 | 6.84% | |
| ZCMD | Zhongchao Inc | 0.97 | -1008.63 | -99.90% | |
| HCTI | Healthcare Triangle, Inc. | 4.39 | -2611.61 | -99.83% | |
| VSEE | Vsee Health, Inc. | 0.69 | -59.42 | -98.86% | |
| ACON | Aclarion, Inc. | 1.63 | -4.52 | -73.50% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.58 | -0.42 | -42.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026